Annotation Detail

Information
Associated Genes
ROS1
Associated Variants
ROS1 REARRANGEMENT ROS1 REARRANGEMENT
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
In a retrospective study, 30 patients were evaluated after crizotinib treatment for stage IV NSCLC confirmed for ROS1 rearrangement. On crizotinib, 24 of the patients achieved objective responses including 5 complete responses. Median progression free survival was 9.1 months and all patients had been pretreated with 1 or more lines of chemotherapy.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1030
Gene URL
https://civic.genome.wustl.edu/links/genes/4941
Variant URL
https://civic.genome.wustl.edu/links/variants/269
Rating
3
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Supports
Drug
Crizotinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
25667280
Drugs
Drug NameSensitivitySupported
CrizotinibSensitivitytrue